Literature DB >> 20932493

Drugs of abuse and human placenta.

Vadivel Ganapathy1.   

Abstract

Drugs of abuse such as cocaine and amphetamines, when used by pregnant women, exert deleterious effects on the fetus. These drugs produce their effects through inhibition of the serotonin transporter, norepinephrine transporter, and dopamine transporter. The inhibition can occur in the pregnant mother as well as in the fetus. These events contribute to the detrimental effects of these drugs on the fetus. However, the role of placenta, which serves as the link between the pregnant mother and the fetus, in the process remains understudied. It has been assumed that the placenta did not play any direct role in the process except that it allowed the passage of these drugs from maternal circulation into fetal circulation. This was before the discovery that the placenta expresses two of the three monoamine transporters. The serotonin transporter and the norepinephrine transporter are expressed on the maternal-facing side of the syncytiotrophoblast, thus exposed to the inhibitory actions of cocaine and amphetamines if present in maternal blood. Inhibition of these transporters in the placenta could lead to elevation of serotonin and norepinephrine in the intervillous space that may cause uterine contraction and vasoconstriction, resulting in premature delivery, decreased placental blood flow, and intrauterine growth retardation. Thus, the placenta is actually a direct target for these abusable drugs. Since the placental serotonin transporter and norepinephrine transporter are also inhibited by many antidepressants, therapeutic use of these drugs in pregnant women may have similar detrimental effects on placental function and fetal growth and development.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20932493      PMCID: PMC3710451          DOI: 10.1016/j.lfs.2010.09.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  43 in total

1.  Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies.

Authors:  G Carrasco; M A Cruz; V Gallardo; P Miguel; A Dominguez; C González
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 2.  Neurotransmitter transporters: fruitful targets for CNS drug discovery.

Authors:  L Iversen
Journal:  Mol Psychiatry       Date:  2000-07       Impact factor: 15.992

Review 3.  Placental transporters relevant to drug distribution across the maternal-fetal interface.

Authors:  V Ganapathy; P D Prasad; M E Ganapathy; F H Leibach
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

Review 4.  Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance.

Authors:  T T Nguyen; Y T Tseng; B McGonnigal; J P Stabila; L A Worrell; S Saha; J F Padbury
Journal:  Placenta       Date:  1999-01       Impact factor: 3.481

Review 5.  Neurotransmitter transporters as molecular targets for addictive drugs.

Authors:  S G Amara; M S Sonders
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

6.  Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.

Authors:  R Kekuda; P D Prasad; X Wu; H Wang; Y J Fei; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

7.  Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line.

Authors:  M E Ganapathy; P D Prasad; W Huang; P Seth; F H Leibach; V Ganapathy
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

Review 8.  Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy.

Authors:  M A Plessinger
Journal:  Obstet Gynecol Clin North Am       Date:  1998-03       Impact factor: 2.844

Review 9.  Cocaine in pregnancy. Recent data on maternal and fetal risks.

Authors:  M A Plessinger; J R Woods
Journal:  Obstet Gynecol Clin North Am       Date:  1998-03       Impact factor: 2.844

10.  Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.

Authors:  X Wu; R Kekuda; W Huang; Y J Fei; F H Leibach; J Chen; S J Conway; V Ganapathy
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

View more
  14 in total

Review 1.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

Review 2.  Management of the Cardiovascular Complications of Substance Use Disorders During Pregnancy.

Authors:  P Kaitlyn Edelson; Sarah N Bernstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-22

3.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

4.  Methamphetamines and pregnancy outcomes.

Authors:  Tricia E Wright; Renee Schuetter; Jacqueline Tellei; Lynnae Sauvage
Journal:  J Addict Med       Date:  2015 Mar-Apr       Impact factor: 3.702

Review 5.  Methamphetamine: burden, mechanism and impact on pregnancy, the fetus, and newborn.

Authors:  Deepika Sankaran; Satyan Lakshminrusimha; Veena Manja
Journal:  J Perinatol       Date:  2021-11-16       Impact factor: 2.521

6.  Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Protective Mechanisms in Preeclampsia.

Authors:  Julie A Vignato; S Banu Gumusoglu; Heather A Davis; Sabrina M Scroggins; Wendy S Hamilton; Debra S Brandt; Gary L Pierce; Boyd A Knosp; Donna A Santillan; Mark K Santillan
Journal:  Reprod Sci       Date:  2022-08-19       Impact factor: 2.924

Review 7.  The omniscient placenta: Metabolic and epigenetic regulation of fetal programming.

Authors:  Bridget M Nugent; Tracy L Bale
Journal:  Front Neuroendocrinol       Date:  2015-09-12       Impact factor: 8.606

8.  White matter microstructure abnormalities and executive function in adolescents with prenatal cocaine exposure.

Authors:  Catherine Lebel; Tamara Warner; John Colby; Lindsay Soderberg; Florence Roussotte; Marylou Behnke; Fonda Davis Eyler; Elizabeth R Sowell
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

9.  Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters.

Authors:  Paul Berveiller; Olivier Mir; Séverine A Degrelle; Vassilis Tsatsaris; Lise Selleret; Jean Guibourdenche; Danièle Evain-Brion; Thierry Fournier; Sophie Gil
Journal:  Invest New Drugs       Date:  2018-10-26       Impact factor: 3.850

10.  Drug Interactions at the Human Placenta: What is the Evidence?

Authors:  Miriam Rubinchik-Stern; Sara Eyal
Journal:  Front Pharmacol       Date:  2012-07-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.